EUVIMEDEUVIMED entdecken
Crossref

Quercetin alleviates hyperoxia‐induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK / PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations

Xianhui Deng, Dan Chen, Anni Xie, Shengpeng Li, Ailing Chen, Qin Zhou, Renqiang Yu

Chemical Biology & Drug Design · 2024

DOI: 10.1111/cbdd.14520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Xianhui Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Affiliated Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, China. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Hyperoxia, Ferroptosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Commission of Health and Family Planning, Medical Key Discipline Program of Wuxi Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Quercetin, a bioactive natural compound renowned for its potent anti‐inflammatory, antioxidant, and antiviral properties, has exhibited therapeutic potential in various diseases. Given that bronchopulmonary dysplasia (BPD) development is closely linked to inflammation and oxidative stress, and quercetin, a robust antioxidant known to activate NRF2 and influence the ferroptosis pathway, offers promise for a wide range of age groups. Nonetheless, the specific role of quercetin in BPD remains largely unexplored. This study aims to uncover the target role of quercetin in BPD through a combination of network pharmacology, molecular docking, computer analyses, and experimental evaluations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchopulmonary DysplasiaHyperoxiaFerroptosisAnimalsInfant, NewbornHumansQuercetinMolecular Docking SimulationCyclooxygenase 2Animals, NewbornAntioxidantsNetwork Pharmacology

Stichwörter der Autor:innen

PTGS2bronchopulmonary dysplasiaferroptosishyperoxiaquercetin

Substanzen

QuercetinCyclooxygenase 2AntioxidantsPTGS2 protein, human

Autor:innen und Institutionen

  • Department of Neonatology, Affiliated Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, China.
  • Department of Physiopathology, Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Research Institute for Reproductive Health and Genetic Diseases, Affiliated Women's Hospital of Jiangnan University, Wuxi, China.
  • Department of Pediatric, Wuxi Yihe Gynaecology and Obstetrics Hospital, Wuxi, China.

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Commission of Health and Family Planning
  • Medical Key Discipline Program of Wuxi Health Commission

Zitieren

APA

Deng, X., Chen, D., Xie, A., Li, S., Chen, A., Zhou, Q., & Yu, R. (2024). Quercetin alleviates hyperoxia‐induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK / PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14520

Vancouver

Deng X, Chen D, Xie A, Li S, Chen A, Zhou Q, et al. Quercetin alleviates hyperoxia‐induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK / PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14520

BibTeX
@article{Deng2024,
  author = {Deng, Xianhui and Chen, Dan and Xie, Anni and Li, Shengpeng and Chen, Ailing and Zhou, Qin and Yu, Renqiang},
  title = {Quercetin alleviates hyperoxia‐induced bronchopulmonary dysplasia by inhibiting ferroptosis through the MAPK / PTGS2 pathway: Insights from network pharmacology, molecular docking, and experimental evaluations},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  doi = {10.1111/cbdd.14520}
}
Kostenlos starten →